HCAT (Health Catalyst) Research & Development: $44.4 Mil (TTM As of Mar. 2026)


HCAT Health Catalyst Inc HCAT
49 GF Score
Price $1.72
GF Value $5.07
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Health Catalyst Research & Development?

Health Catalyst HCAT -1.71% 49 Research & Development is $44.4 Mil as of Mar. 2026. GuruFocus rates HCAT with a GF Score™ of 49/100 and a GF Value™ of $5.07 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Health Catalyst's Research & Development for the three months ended in Mar. 2026 was $9.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $44.4 Mil.

Health Catalyst  (NAS:HCAT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Health Catalyst Research & Development Related Terms

Health Catalyst Research & Development Historical Data

* Premium members only.

The historical data trend for Health Catalyst's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Health Catalyst Research & Development Chart

Health Catalyst Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 62.73 75.68 72.63 57.95 49.77

Health Catalyst Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.19 12.39 12.28 9.91 9.78
HCAT
49GF Score
Health Catalyst Inc HCAT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Health Catalyst Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $44.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $44.4 Mil mean?
Health Catalyst (HCAT) has a Research & Development of $44.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Health Catalyst and its competitors.
Is Health Catalyst's Research & Development too high?
Health Catalyst's current Research & Development is $44.4 Mil. Overall, Health Catalyst has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's Research & Development compare to CCLD and DH?
Health Catalyst's Research & Development of $44.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Health Catalyst and its competitors. Health Catalyst's current Research & Development is $44.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $5.07, compared to a current price of $1.72 — trading 66.1% below its estimated fair value. The current Research & Development is $44.4 Mil. Health Catalyst's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Health Catalyst (HCAT), the current Research & Development is $44.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Health Catalyst (HCAT) Overvalued in 2026?

Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued. The current stock price of $1.72 is trading 66.1% below its estimated GF Value™ of $5.07. GuruFocus considers Health Catalyst to be Possible Value Trap.

Key valuation signals for HCAT:

  • Research & Development: $44.4 Mil
  • GF Value™: $5.07 vs. price of $1.72 (66.1% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Health Catalyst Business Description

Other Exchanges 2YP:Germany
Address 10897 South River Front Parkway, Suite 300, South Jordan, UT, USA, 84095
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
49GF Score

Get the complete analysis for HCAT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price
$5.07
GF Value